Advances in molecular and immunohistochemical techniques have ushered the NSCLC space into an exciting era of personalized medicine and improved outcomes – and a plethora of novel therapies are now in clinical development. Despite this, and whether patients fit into one of the actionable alteration subtypes of NSCLC or not, most will progress and/or develop resistance to currently available treatments.
The 2nd NSCLC Drug Development Summit returns as the only industry-led forum for large biopharma, biotech and academic leaders to address mechanisms of drug resistance, spearhead progress in molecular subtyping and define practice-changing drug sequencing and combinations for the largest solid tumor indication.
We will be focusing on:
- Refining molecular testing of NSCLC tumors and making next-generation sequencing tools more accessible in the clinical setting
- Investigating novel immune checkpoints and checkpoint inhibitor sequencing or combinations with surgery, chemo and/or radiotherapy where applicable, to define therapeutic options with better safety and efficacy outcomes in second line or beyond
- Overcoming resistance mechanisms and patient progression after TKI treatment approaches for NSCLC tumors with actionable alterations
- Providing clarity on tumor biopsy testing guidelines to promote effective personalized treatment of patients
- Identifying truly transformative investigational drugs for use in the early vs. late-stage NSCLC setting and cut through the noise of increasingly complex therapeutic options
- Exploring trial design challenges to watch out for and tips for patient inclusion/exclusion criteria
Join the NSCLC Summit for 3 jam-packed days of presentations, panel discussions and interactive workshops with over 20 expert industry speakers.
There has never been a more important time to rally together to defeat NSCLC and radically change patients lives.
To know more visit: https://bit.ly/3mpftud